NASDAQ
02.09.25 | 22:00
1,030 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | ALX Oncology doses first patient in phase 1 trial of EGFR cancer drug | 1 | Investing.com | ||
| 12.08. | ALX Oncology Q2 2025 slides: biomarker strategy shows promise as cash runway extends | 6 | Investing.com | ||
| 12.08. | ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 293 | GlobeNewswire (Europe) | - Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference... ► Artikel lesen | |
| 12.08. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | ALX Oncology Holdings' Earnings: A Preview | 3 | Benzinga.com | ||
| 05.08. | ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 | 1 | GlobeNewswire (USA) | ||
| 12.06. | ALX Oncology berichtet über Ergebnisse der Jahreshauptversammlung | 5 | Investing.com Deutsch | ||
| 12.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 27.05. | H.C. Wainwright maintains ALX Oncology stock Buy rating | 4 | Investing.com | ||
| 20.05. | ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event | 161 | GlobeNewswire (Europe) | - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the... ► Artikel lesen | |
| 13.05. | ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 | 3 | GlobeNewswire (USA) | ||
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.05. | ALX Oncology GAAP EPS of -$0.58 misses by $0.10 | 2 | Seeking Alpha | ||
| 08.05. | ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update | 348 | GlobeNewswire (Europe) | Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase... ► Artikel lesen | |
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | What's Next: ALX Oncology Holdings' Earnings Preview | 1 | Benzinga.com | ||
| 02.05. | ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | 3 | GlobeNewswire (USA) | ||
| 25.04. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 25.04. | ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials | 1 | FierceBiotech | ||
| 25.04. | ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma | 222 | GlobeNewswire (Europe) | - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,824 | +0,59 % | EQS-DD: Evotec SE: Dr. Christian Wojczewski, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
27.08.2025 / 15:03... ► Artikel lesen | |
| MODERNA | 20,800 | +0,02 % | Moderna, Inc.: Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism | CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at... ► Artikel lesen | |
| NOVAVAX | 6,515 | +0,37 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| CRISPR THERAPEUTICS | 44,600 | -1,33 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
| INOVIO PHARMACEUTICALS | 2,220 | 0,00 % | INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug | ||
| INTELLIA THERAPEUTICS | 10,025 | +2,32 % | Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus | ||
| EDITAS MEDICINE | 2,072 | -2,54 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,490 | +5,60 % | Defence Therapeutics Inc.: Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth | Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,830 | +1,51 % | S&P Dow Jones Indices: Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 | NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,00 | +2,44 % | Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2 | WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) announced a profit for its second quarter that Increases, from last yearThe company's earnings totaled $240.53 million, or $1.23 per... ► Artikel lesen | |
| EXELIXIS | 31,900 | -0,13 % | EXELIXIS, INC. - 8-K, Current Report | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,123 | +1,63 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
| VAXART | 0,305 | -18,80 % | Vaxart, Inc.: Vaxart Granted Extension by Nasdaq to Regain Compliance | - Company must regain compliance with the Nasdaq Bid Price Rule on or before the October 17, 2025 deadline - SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT)... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 122,90 | +0,86 % | Neurocrine Biosciences Inc Q2 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) announced a profit for its second quarter that Increased from the same period last year and beat the Street estimates.The company's bottom... ► Artikel lesen |
ALX ONCOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.